Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 2Phase 3 1Phase 2/3 1

Status

Completed 4Terminated 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 3Thoracic 1Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 150Lung Neoplasms 58Pancreatic Neoplasms 34Neoplasms 20Neoplasm Metastasis 15Breast Neoplasms 15Adenocarcinoma of Lung 15Brain Neoplasms 14Adenocarcinoma, Bronchiolo-Alveolar 13Glioblastoma 12Non-Squamous Non-Small Cell Lung Cancer 11Head and Neck Neoplasms 11Gliosarcoma 11Squamous Cell Carcinoma of Head and Neck 10Carcinoma, Hepatocellular 10Colorectal Neoplasms 8Carcinoma, Renal Cell 8Esophageal Neoplasms 6Urinary Bladder Neoplasms 5Gallbladder Neoplasms 5Colonic Neoplasms 5Central Nervous System Neoplasms 5Carcinoma, Squamous Cell 5Adenocarcinoma 5Rectal Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Liver Neoplasms 4Kidney Neoplasms 4Fallopian Tube Neoplasms 4

Interventions

Cisplatin 39Radiotherapy 21Carboplatin 21Cetuximab 20Paclitaxel 19Docetaxel 17Radiotherapy, Intensity-Modulated 15pembrolizumab 14Fluorouracil 13Drug Therapy 10Nivolumab 8Radiation 6cemiplimab 5atezolizumab 5Panitumumab 5Oxaliplatin 5Erlotinib Hydrochloride 5Chemoradiotherapy 5Afatinib 5Surgical Procedures, Operative 4durvalumab 3Surveys and Questionnaires 3Methotrexate 3Leucovorin 3Lapatinib 3130-nm albumin-bound paclitaxel 3toripalimab 2palbociclib 2osimertinib 2dacomitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Squamous Cell × Erlotinib Hydrochloride × Clear all
NCT00942734 2025-05-01

Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

M.D. Anderson Cancer Center

Phase 2 Completed
49 enrolled 5 charts
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00563784 2019-11-20

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

M.D. Anderson Cancer Center

Phase 2 Completed
68 enrolled 11 charts
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Adenocarcinoma, Clear Cell, Carcinoma, Giant Cell

NCT00369512 2017-05-30

RAD0503

University of Alabama at Birmingham

Phase 2 Completed
15 enrolled 9 charts
Tumor-Agnostic

Carcinoma, Squamous Cell, Neoplasms

NCT01009203 2015-08-10

Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma

New Mexico Cancer Research Alliance

Phase 2 Terminated
13 enrolled 8 charts
Tumor-Agnostic

Carcinoma, Squamous Cell

NCT00476476 2015-05-07

Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar

Dana-Farber Cancer Institute

Phase 2 Completed
41 enrolled 7 charts
Tumor-Agnostic

Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡